After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition

In March, as Novo Nordisk’s core semaglutide patent expired in India, the Indian market formally entered the generic competition phase. Reuters reported on March 19 that after the patent expired in India, more than 40 Indian pharmaceutical companies planned to launch over 50 semaglutide-related brands, with major players including Sun Pharma, Dr. Reddy’s, Lupin, Zydus, Torrent, Glenmark, Alkem, and Eris. For the GLP-1 industry, this is not an ordinary patent expiry, but the first time semaglutide has entered a highly open, genuinely competitive phase in a mega-population market, with dense participation from local generic-drug companies.

What makes this event important, first of all, is that it has rewritten the pricing system. In the past, Ozempic and Wegovy in India were aimed largely at a relatively limited group with stronger purchasing power, and their prices were well beyond the reach of most ordinary patients. Reuters and Bloomberg disclosed that after the patent expired, the monthly treatment price launched by Indian companies quickly dropped, with the lowest falling to around 1,290 rupees, or about US$14; Reuters further noted that prices across different brands and dosage strengths had already fallen to a range of roughly 750 rupees to 4,200 rupees. Compared with the originator products, the decline in many cases reached 50% to 80%, or even lower. That means semaglutide in India is no longer just a high-priced innovative drug, but has started to become a treatment product that genuinely enters the discussion of broad accessibility.

The price change itself already says a great deal. For years, GLP-1 drugs were largely seen as high-priced therapies dominated by Europe, the United States, and some middle- to high-income markets. High R&D costs, complex formulation processes, injection devices, and cold-chain requirements all helped support that pricing structure. India is different this time. As soon as the patent expired, the local generic-drug system moved almost simultaneously, and several leading pharmaceutical companies brought prices down to levels far below the originator drugs in a very short time. This is not a gradual price decline, but a visible pricing cliff. From a commercial standpoint, this kind of cliff directly changes the threshold for patient entry, and it also causes the pricing structure that originator companies had relied on under patent protection to destabilize rapidly in India.

More importantly, India is not a marginal market. It is itself one of the world’s largest generic-drug producers, and it also has a huge base of diabetes and obesity patients. Reuters noted that India’s obesity-drug market is currently worth about 15 billion rupees and could grow to 80 billion rupees by 2030. For Novo Nordisk, India is not a market that can be easily abandoned; for Indian domestic drugmakers, this is not an ordinary generic-drug opportunity, but a collective charge around the next major global blockbuster category. Patent expiry combined with huge market size means that this competition was never going to be mild from the outset.

From the competitive structure, the most striking feature of the Indian market this time is not just low prices, but the sheer number of participants and the complexity of their strategies. Reuters, Fierce Pharma, and multiple Indian media outlets all noted that more than ten major companies have already entered first, and in the short term there are expected to be more than 40 companies and 50-plus brands in the market. What different companies are launching is not just the same copied product, but a full layout around dosage forms, branding, devices, price bands, and channel models. Some companies are launching multi-dose pens, some are starting with vial formats, some emphasize low starting doses, and some are putting oral and injectable versions into their commercial portfolios at the same time. In other words, from day one this competition has not been a simple price war, but a multi-layered competition in price, dosage form, device, channel, and brand.

This point is especially worth noting. Because when the active ingredient is the same, room for product differentiation often shifts to the device and user experience. Novo Nordisk’s original products have long relied on the convenience and standardized dosing experience of prefilled injection pens, but Indian companies have not all chosen to follow that same path. Some companies are opting for reusable pens, some for vials or ampoules with syringes, and some have begun placing oral versions into their commercialization mix as well. Cost is of course part of the reason, but more importantly, it shows that Indian companies are not satisfied with simply “making the same drug.” They are trying to capture different price bands and different patient groups more quickly through different product structures. At the generic stage, devices and ease of use may actually become one of the most practical dimensions of competition.

The change at the channel level is equally clear. In the originator-drug era, GLP-1s in India were concentrated more in major cities, specialist centers, and patient groups with stronger ability to pay. After the patent expired, one of the biggest advantages of Indian domestic drugmakers lies precisely in their deeper sales penetration, broader field-force systems, and stronger retail reach. Reuters noted that many companies have explicitly identified smaller cities and regions insufficiently covered by originator companies as their key entry points. This means semaglutide’s expansion path in India is unlikely to be one of gradually scaling up first in the premium market; instead, it may rapidly move downward through the generic-drug system. Once low-price versions enter more cities and more channels, the structure of semaglutide users in India will also change accordingly.(reuters.com)

At the same time, the patient-management system is beginning to be redefined. After prices fall, the question is no longer just “can patients afford it,” but “how will they stay on treatment long term, who will manage them, and how will adherence be maintained?” Reuters reported on March 24 that India’s drug regulator has already begun tightening oversight of unauthorized sales and promotion of weight-loss drugs, and has inspected 49 entities, including slimming clinics, wholesalers, and retailers. What regulators are worried about is that as low-cost generic drugs spread rapidly, the market may see improper prescribing, misleading promotion, use without physician guidance, and a shift toward cosmetic use or misuse. This shows that in India, GLP-1 competition is no longer just a commercial contest between drugmakers, but is also becoming a regulatory and patient-management issue.

This step is in fact extremely important. GLP-1 drugs are not ordinary short-course medicines; they are typically used over a long period, with gradual dose escalation, side-effect management, and lifestyle intervention. Lower prices can certainly expand the patient base, but if patient education, physician management, and medication supervision do not keep up, the market could quickly enter a situation where “the drug is sold more widely, but used more chaotically.” The concentrated inspections of违规 promotion and unauthorized sales by Indian regulators are, in essence, a response to exactly that risk. When the market moves from a high-price, low-penetration stage into a low-price, fast-expansion stage, the patient ecosystem becomes the new focus of both competition and regulation.

For originator drugmakers, the changes in India have already forced them to adjust strategy in advance. Reuters and related reports have noted that before the patent expired, Novo Nordisk had already reduced the price of Wegovy in India, in hopes of slowing market-share erosion through early pricing adjustment. But given the current density of competition, it will be difficult for originator companies to continue relying on the post-patent high-price system to maintain absolute advantage in India. What is more likely from here is two kinds of defensive action: one is maintaining premium users through devices, brand, and physician recognition; the other is widening the gap through next-generation products and more complete patient service systems. In other words, the Indian market is forcing originator companies to shift from “selling patented drugs” to “selling brand, device, and a complete treatment experience.”

At a deeper level, India’s patent-expiry event is not just India’s own story, but a preview of the future shape of the global GLP-1 market. Semaglutide will not lose patent protection only in India. Multiple countries and regions will enter similar phases over the next few years. What makes India especially important is that it almost simultaneously possesses three conditions: a sufficiently large patient population, sufficiently strong generic-drug manufacturing capability, and a sufficiently intense price-competition environment. What happens first in a market like this often becomes an important sample for other countries observing the future competitive landscape.

When the lens shifts to China, the reference value of this event becomes even stronger. China and India are the world’s two most populous countries, and both also bear a long-term burden of obesity and metabolic disease. The current price collapse in India has in fact already established a new price reference point for the Asian market in advance. The public will begin to ask: if India can have monthly treatment prices at the US$14 level, why should China not eventually be lower and more widely accessible? This will directly affect the pricing expectations of originator drugmakers in China and other Asian markets, and will also force companies to prepare defensive moves earlier before patent expiry. India is not fighting a price war in isolation; it is changing the entire Asian market’s imagination of a “reasonable price” for GLP-1 in advance.(bloomberg.com)

But China and India will not follow the same path. India’s core advantages lie in low-cost generics, rapid rollout, and strong channels. China is more likely to develop a different structure. China’s drug review, prescription management, consistency evaluation, and clinical equivalence requirements are generally stricter, which means the pace of post-patent generic opening will not be as dense and intense as in India. At the same time, China has strong manufacturing capabilities in peptide synthesis, sterile formulations, cold-chain logistics, and complex injection devices. Combined with the rapid advancement of local companies in GLP-1, dual-target, triple-target, and oral small-molecule directions, China’s future competitive structure is more likely to feature high-quality generics, device innovation, and original innovation moving in parallel, rather than simple low-cost copying alone. The key difference here is that India has proven how far prices can fall first, while China may eventually determine how far quality and innovation can go. This judgment is an inference based on the current market structure and industrial capabilities of China and India.

Back to India itself, this competition is likely to go through a clear reshuffling over the next three to five years. Although more than 40 companies and 50-plus brands will flood in over the short term, those that remain in the end may not be the ones with the very lowest prices, but rather those that can stand out in physician trust, quality stability, channel coverage, patient management, and sustained brand investment. GLP-1 is not an ordinary cold medicine. Its long-term treatment nature means that once patients establish a habit of use, future choices will not depend only on one-time price. So the Indian market will be extremely crowded in the short term, but over the longer run is likely to move toward a situation where a small number of brands win out while the rest are marginalized.

Taken together, what semaglutide patent expiry has brought to India is not just a drop in drug prices, but a full market reconstruction. The pricing system has been broken through, competition has shifted from single-layer to multi-layered, patient management is becoming a new battleground, originator companies are being forced to adjust in advance, and subsequent markets such as China have already begun to be shaped by the expectation effect. What truly matters here is not how cheaply one brand can sell, but that a molecule once highly concentrated within a high-priced innovative-drug system has, for the first time in a large market, been placed into an environment of open competition. What is happening in India now is not just the launch of generics, but the first large-scale rewriting of the global commercial logic of GLP-1.